Qiming Venture Partners VI, L.P.'s Form 4 filing
Alamar Biosciences, Inc.ALMR · filed Nov 3, 2026
- Accession no.
- 0001231919-26-001531
- Filed
- Nov 3, 2026, 4:15 PM ET
- Trade date
- Oct 30-Nov 2, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 24 non-derivative transactions. Open-market sales total $5.68M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Qiming Venture Partners VI, L.P.CIK 0001733278 | 10% Owner |
| Qiming Managing Directors Fund VI, L.P.CIK 0001733282 | 10% Owner |
| Qiming Venture Partners VIII-HC, L.P.CIK 0001910025 | 10% Owner |
| Qiming Corporate GP VI, Ltd.CIK 0002059127 | 10% Owner |
| Qiming Venture Partners VIII Investments, LLCCIK 0002129618 | 10% Owner |
| Qiming GP VIII-HC, LLCCIK 0002129671 | 10% Owner |
| Qiming GP VIII, LLCCIK 0002129740 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Common Stock | SSaleDisposed | −1,309 | $29.93F1 | −$39,178.37 | 162,882 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −1,080 | $30.70F3 | −$33,156 | 161,802 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −92 | $31.96F4 | −$2,940.32 | 161,710 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −31 | $33.31F5 | −$1,032.61 | 161,679 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −48,659 | $29.93F1 | −$1,456,363.87 | 6,053,320 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −40,112 | $30.70F3 | −$1,231,438.4 | 6,013,208 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −3,400 | $31.96F4 | −$108,664 | 6,009,808 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −1,169 | $33.31F5 | −$38,939.39 | 6,008,639 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −11,354 | $29.93F1 | −$339,825.22 | 1,412,427 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −9,359 | $30.70F3 | −$287,321.3 | 1,403,068 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −793 | $31.96F4 | −$25,344.28 | 1,402,275 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −273 | $33.31F5 | −$9,093.63 | 1,402,002 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −13,593 | $29.93F1 | −$406,838.49 | 1,691,003 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −11,205 | $30.70F3 | −$343,993.5 | 1,679,798 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −950 | $31.96F4 | −$30,362 | 1,678,848 | Indirect | |
| Oct 30, 2026 | Common Stock | SSaleDisposed | −327 | $33.31F5 | −$10,892.37 | 1,678,521 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −763 | $29.84F9 | −$22,767.92 | 160,916 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −3 | $30.63 | −$91.89 | 160,913 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −28,404 | $29.84F9 | −$847,575.36 | 5,980,235 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −131 | $30.63 | −$4,012.53 | 5,980,104 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −6,628 | $29.84F9 | −$197,779.52 | 1,395,374 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −30 | $30.63 | −$918.9 | 1,395,344 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −7,935 | $29.84F9 | −$236,780.4 | 1,670,586 | Indirect | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −36 | $30.63 | −$1,102.68 | 1,670,550 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.49, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1), (3), (4), (5) and (9) to this Form 4.
Referenced by the price of 4 transactions in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.46, inclusive.
Referenced by the price of 4 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.52 to $32.465, inclusive.
Referenced by the price of 4 transactions in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.68 to $33.59, inclusive.
Referenced by the price of 4 transactions in Table I.
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.44, inclusive.
Referenced by the price of 4 transactions in Table I.